The administration of an aqueous-ether extracted residue of Brucella abortus (Bru-Pel) inhibits development of transplanted osteogenic sarcomas in mice as evidenced by a decrease in mortality. At least one mechanism through which Bru-Pel modulates host resistance is activation of macrophages of the reticuloendothelial system. Peritoneal macrophages harvested from mice receiving BruPel were cytotoxic for osteogenic sarcoma cells in vitro, limited the replication of vaccinia virus in cell cultures, and demonstrated enhanced emittance of chemiluminescence during phagocytosis of zymosan particles or Candida albicans. The concept of reticuloendothelial system activation was further supported by the evidence that administration of Bru-Pel enhanced resistance of mice to challenge with a lethal inoculum of Listeria monocytogenes. These observations support the hypothesis that Bru-Pel shares a number of characteristics with recognized immunomodulating agents and that one mechanism by which it modulates host resistance to tumors, to virus infections, and to challenge with L. monocytogenes is through activation of macrophages.
A significant body of evidence has developed which documents that a number of bacteria have the capacity to modulate host resistance. Corynebacteriumparvum (26) and BCG (11) are the most widely recognized immunomodulators and currently are being utilized in the treatment of malignancies in humans. Other organisms, including Proprionobacterium acnes (2, 4) and Brucella abortus (3, 15, 17, 31) , have also been shown to alter host defense mechanisms. In 1964, Stinebring and Youngner (28) demonstrated that intravenous inoculation of live B. abortus organisms induced interferon production in mice. Subsequently, Billiau and co-workers (1) , utilizing both live and killed preparations of bruceliae, confirmed the induction of interferon in mice by these organisms and showed that experimental animals could be protected against challenge with vaccinia virus. These studies were extended by Hirnle (13) , who demonstrated that infection with B. abortus was protective in mice against a transplantable sarcoma and by other workers who reported protection against Rauscher ieukemia, L1210 leukemia (30) , and Ehrlich ascites carcinoma (23) . Since the inoculation of viable organisms has been associated with undesirable side effects and preparations of whole organisms contain extraneous antigenic material, a number of investigations have been directed toward extracting the active components from bacterial organisms which modulate host resistance. Utilizing this approach Youngner and co-workers (32) found that an aqueous ether-extracted preparation of B. abortus, which they designated as Bru-Pel, was a nontoxic interferon inducer. Furthermore, mice pretreated with Bru-Pel were protected against a lethal infection with Semliki Forest virus. In our laboratory the interferon-inducing capacity of Bru-Pel was confirned as was the ability of Bru-Pel to enhance host resistance to other viral infections (17) . The time relationship of the administration of Bru-Pel to challenge with virus strongly suggested that the antiviral activity of Bru-Pel was a function of nonspecific immunomodulation of host defense mechanisms as well as to the induction of interferon. More recently the modulation of host resistance by Bru-Pel has been broadened to include antitumor as well as antiviral activity. Keleti et al. (15) reported protection of mice from death due to sarcoma 180 when Bru-Pel was administered 7 days before, simultaneously with, and as late as 7 days after inoculation of sarcoma cells.
The purpose of the experiments in this report was to determine the capacity of Bru-Pel to enhance host resistance to the development of a transplantable osteogenic sarcoma (OSG) in mice and to investigate the mechanism of both its antitumor and antiviral activity.
(Portions of this work were presented at the 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, N.Y., [12] [13] [14] October, 1977.) MATERIALS AND METHODS Mice. C57BL/6J female mice (Jackson Laboratories, Bar Harbor, Maine) were used in all experiments at 6 to 10 weeks of age and were given food and water ad libitum.
Immunomodulators, interferon inducers, and viruses. Bru-Pel, which is an aqueous-ether extracted residue of the nonpathogenic strain 456 of B. abortus (ATCC 7705), was received as a lyophilized powder from J. Youngner, University of Pittsburgh, Pittsburgh, Pa., as part of the Antiviral Substances Program of the National Institute of Allergy and Infectious Diseases. This material was suspended in phosphate-buffered saline (PBS) to a concentration of 10 mg/ml. Each mouse received 1,000 yg of Bru-Pel intraperitoneally (i.p.) in 0.1 ml. C. parvum was received from Burroughs-Wellcome, Research Triangle, N.C., as a killed vaccine containing 7 mg (wet weight) of organisms per ml. Animals were inoculated i.p. The vaccinia virus pool utilized was prepared in mouse embryo fibroblast (MEF) cells and titered 2 x 106 plaque-forming units (PFU) per ml in MEF cells.
The original virus stock was obtained from K. Hable, National Institutes of Health, Bethesda, Md. Newcastle disease virus (NDV) was obtained from S. Baron (National Institutes of Health, Bethesda, Md.). The pool used in these studies was prepared in embryonated chicken eggs and titered 4 x 108 PFU/ml in fetal lamb kidney cells.
Cell cultures and media. Secondary cultures of syngeneic MEF cells were used in both the antitumor and antiviral experiments. A continuous line of OGS cells that has remained tumorigenic upon i.p. or subcutaneous inoculation into C57BL/6J mice was established from a primary osteogenic sarcoma of the vertebrae induced in C57BL/6J mice by irradiation with plutonium-239 (provided by G. Taylor, Division of Radiobiology, University of Utah, Salt Lake City). Histological sections of the primary tumor demonstrated the characteristics of an osteogenic sarcoma. The osteoid component was lost with in vitro or in vivo passage, and s.c. inoculation of the OGS cell line produced an undifferentiated sarcoma. All cell cultures were propagated and maintained on Eagle minimal essential medium (MEM) containing 10% fetal bovine serum, 300 jig of glutamine per ml, 100 U of penicillin per ml, and 50 ,tg of streptomycin per ml. Cells were incubated in humidified 5% CO2 atmosphere at 37°C.
PC. Peritoneal cells (PC) were harvested from experimental and control mice 14 days after Bru-Pel, C. parvum, or poly(ICLC) administration as described previously (21) . Briefly, mice were sacrificed by cervical dislocation, and the peritoneum was exposed. The peritoneal cavities were irrigated with 5 to 6 ml of cold MEM without serum and containing 2.5 U/ml of sodium heparin. The peritoneal washings were collected and pooled from animals of the same group. Fluids containing PC were then centrifuged at 350 x g. For the chemiluminescence procedure, the pellet was resuspended in RPMI-1640 (Flow Laboratories, Inc., Rockville, Md.) with 20 mM N-2-hydroxyethyl piperazine-N'-2-ethanesulfonic acid buffer, 0.1% NaHCO3, 10% fetal bovine serum, and glutamine, penicillin, and streptomycin at the concentrations listed for MEM. For demonstration of in vitro antitumor and antiviral activity, PC were resuspended in MEM with 10% serum. Viable PC were then counted by using trypan blue (0.006%) exclusion.
Preparation of opsonized particles. Two hundred milligrams of zymosan (Schwarz/Mann, Orangeburg, N.Y.) was washed once in 10 ml of PBS, centrifuged at 350 x g, and resuspended in 10 Chemiluminescence procedure. Scintillation counting was performed by the procedure of Hemming et al. (9) . A Beckman LS 100C system (Beckman Instruments, Inc., Fullerton, Calif.) was employed for liquid scintillation counting in ambient light and temperature in the out of phase mode with the front photomultiplier disconnected. Beckman Poly Q vials (Beckman Instruments) were dark adapted for 18 to 24 h before use. To duplicate vials, 0.5 ml of a PC suspension from treated or control animals was added (5 x 106 PC), along with 2.8 ml of RPMI-1640 medium and 0.2 ml of either the zymosan or C. albicans suspension. The resultant ratio of zymosan or C. albicans particles to PC was ca. 100:1. Vials containing medium with 5 x 106 PC adjusted to a total volume of 3.5 ml served as controls. Samples were counted for 1 min at ca. 10-min intervals for 2 h. Results are graphed as the average counts per minute for duplicate vials at each 10-min interval after addition of reactants. Infrequently, we observed a random count-per-minute determination for an individual vial to be strikingly elevated above all previous and subsequent values. Such discrepancies were noted at an approximate frequency of 1 of every 100 determinations. Accordingly, animals, tumor development was completely inhibited during the observation period. These data suggested that Bru-Pel was effective in enhancing host resistance to the development of tumors after inoculation of OGS cells.
In the next experiment the treatment schedule was expanded to determine how late in the course of tumor development host resistance could be enhanced. Results reported previously from our laboratory that the growth of OGS cells is inhibited by interferon in vitro and in vivo (6) and the fact that Bru-Pel induces interferon in mice (3, 17, 32) suggested that interferon might be a factor in the observed efficacy of Bru-Pel in suppressing tumor development. To control for this variable, we gave groups of animals either NDV or poly(ICLC) at 14 days before or just prior to OGS cells. The poly(ICLC) was utilized as a synthetic interferon inducer which stimulates high levels of interferon in mice. One group of animals was inoculated with each interferon inducer 14 days before the tumor cells to control for the possibility that these inducers might also act as a nonspecific modulator of host resistance. The results are also summarized in Table 1 (experiment 2). After 2 months of observation, the mortality of tumorinoculated mice was significantly reduced when Bru-Pel was administered at either -14, 0, or 3 days after, but not at 7 days after tumor cells. C. parvum was also effective when given 14 days Fig. 1 . The virus yields obtained from the cultures that received PC from either normal mice or those that received poly(ICLC) were similar to those obtained from the virus controls for all 3 days sampled (less than 0.7 logs per ml difference). In contrast to these results, the macrophages from the BruPel-and C. parvum-treated mice markedly decreased the virus yield. The sample obtained 24 h after infection from monolayers overlaid with PC from either Bru-Pel-or C. parvum-treated mice contained ca. 102 PFU of vaccinia virus per ml compared with 104 PFU/ml in samples from cultures containing PC from control mice. Subsequent samples taken at days 2 and 3 showed similar 100-to 1,000-fold differences. The PC from C. parvum-treated mice, however, appeared to be more effective in reducing virus yield than the PC from Bru-Pel-inoculated animals. These results clearly indicate that macrophages from animals exposed to these immunomodulators have an enhanced capacity to limit viral replication in vitro in the absence of other components of the host defenses.
Enhanced chemiluminescence in macro- Another measure of activation of macrophages is enhanced chemilummescence during phagocytosis of zymosan or other particles (25) . To further document the enhanced metabolic activity of macrophages from Bru-Pel-exposed mice, we next determined the effect of Bru-Pel on the emittance of chemiluminescence by glass-adherent PC. One representative experiment demonstrating the chemiluminescence emitted by PC from control and Bru-Pel-treated mice is depicted in Fig. 2 . PC from animals exposed to Bru-Pel displayed enhanced chemiluminescence compared to those from control animals during phagocytosis of either zymocan or C. albicans. The counts per minute emitted by PC alone from Bru-Pel and control groups were similar to each other but strikingly less than the chemiluminescence from vials containing an opsonized particle with either PC preparation. PMN in the preparations could result in an apparent difference between the experimental groups; differential cell counts were performed with each PC preparation. The differential counts of PC from Bru-Pel-treated mice were 26% lymphocytes, 68% macrophages, and 6% PMN; PC from control mice had similar differential counts. The similarity in the differential cell counts in this experiment indicates that the enhanced chemiluminescence in PC from BruPel-treated mice was not due to contaminating PMN. Enhanced host resistance to L monocytogenes in Bru-Pel-inoculated mice. One widely accepted manifestation of increased phagocytic cell activity is enhancement of host resistance to infection with L. monocytogenes (20) . In the final series of experiments, groups of 10 animals were challenged i.p. with the twofold serial dilutions of L. monocytogenes 14 days after administration of Bru-Pel or PBS. In Table  3 the results of one representative experiment are shown. Animals treated with Bru-Pel displayed a markedly enhanced resistance to mortality from listeria infection when compared with control mice. The LD50 for mice given PBS was 3.8 x 105 CFU, while only one of the 50 animals that had received Bru-Pel died. These results confirm our evidence from in vitro studies that Bru-Pel may nonspecifically enhance host resistance by activation of cells (macrophages) of the reticuloendothelial system. DISCUSSION Immunomodulators are currently being used in the treatment of human malignancies (26) . Although C. parvum and BCG are the most widely utilized modulators of host resistance, other agents are recognized to have similar effects (4, 7, 11, 14-16, 21, 31) . For a number of years B. abortus has also been recognized to have the capacity to modulate host resistance as evidenced by interferon induction (17, 28) , protection against viral infections (3, 17, 32) , and inhibition of tumor growth (15, 19, 23, 30) .
Other workers have previously demonstrated that separated bacterial cell components or extracts may have many of the effects of whole cells. The advantage of a better-defined product which would retain many of the biological activities of the whole organism preparation, yet have significantly reduced toxicity is apparent. A number of years ago Williams and Dubois (31) showed that methanol extracts oftubercle bacilli could enhance host resistance to infection. More recently, Lamensans and co-workers (18) have demonstrated that an extract from nonpathogenic mycobacteria protected mice against L1210 leukemia, a lymphoid leukemia, and Ehrlich ascitic carcinoma, as well as enhancing host resistance to a murine picornavirus. Utilizing an extract of P. acnes, Fischbach and Glasgow (4) have shown that the extract had a similar effect on interferon production by macrophages as a killed preparation of whole organisms. Youngner et al., utilizing B. abortus, carried out an ether extraction procedure yielding a nonviable insoluble residue (Bru-Pel) which retained the activity of the intact organism to induce interferon and which protected mice against Semliki Forest virus (3, 32). In our own laboratory we extended these studies to demonstrate that Bru-Pel enhanced protection against viral infections independent of its capacity to induce interferon (17) . The results from Youngner's laboratory (3, 15, 32) and our own previous work suggest that immunomodulators may provide the additional advantage of enhancing host resistance to viral infection in patients being treated for their malignancy.
If Bru-Pel is to be further evaluated as an immunomodulator, then additional data on its efficacy in enhancing host resistance to tumors must be obtained. Keleti and co-workers (15) have previously demonstrated protection against S-180 cells in mice. The present study extends the investigation of the antitumor activity of Bru-Pel to a murine OSG. OSG is probably the most common malignant primary tumor of bone in humans, and, although the prognosis of patients with this malignancy has improved, therapy remains far from optimal. We report here the efficacy of Bru-Pel in preventing the development of tumors in experimental animals INFECT. IMMUN. on December 21, 2017 by guest http://iai.asm.org/ Downloaded from after administration of 100% lethal inoculum of OSG cells. This effect was observed not only with pretreatment, but also when Bru-Pel was administered after tumor cells were inoculated. Although a detailed comparison with the activity of C. parvum was not the purpose of this investigation, Bru-Pel appeared to be at least as active in this experimental model. The results certainly suggest that further evaluation of the antitumor activity of Bru-Pel in other experimental models is indicated.
One interesting difference between Bru-Pel and P. acnes or C. parvum is that Bru-Pel actively induces interferon while the forner immunomodulators inhibit interferon production, both in the intact animal and by macrophages in vitro. Although the difficulty in separating interferon induction from the immunomodulating effects of Bru-Pel preclude a definitive experiment, the present data suggest that the predominant factor in the antitumor activity of Bru-Pel is not the induction of interferon. In these experiments other interferon inducers failed to modulate resistance to the tumors. On the other hand, interferon probably is a factor in the antiviral activity of Bru-Pel when the substance is administered close to the time of virus challenge. Thus Bru-Pel may have a twofold effect on viral infections: induction of interferon and modulation of other host defenses. This evidence for differences in effects on host cells and on different determinants of host resistance further supports the interest in Bru-Pel as a potential therapeutic agent.
The second series of studies reported here were directed toward elucidating the mechanism of action of Bru-Pel. Immunomodulators are associated with alteration of macrophage function, including increased movement and spreading of cells on surfaces, increased intracellular bactericidal activity as compared to unstimulated cells, and the capacity to destroy tumor cells and to inhibit progression of virus infection in tissue culture (10-12, 21, 22) . The results of the experiments reported here indicate that BruPel activates macrophages as evidenced both by the capacity to limit the progression of viral replication in a tissue culture system and to be cytocidal for tumor cells. In contrast with some previous reports, however, the macrophages activated by Bru (16) . Possible explanations for these observations include the presence of a fetal antigen or manifestations of an endogenous virus which results in alteration of surface antigens on the normal embryo cell used as nonmalignant controls. The data also indicate that Bru-Pel is an effective stimulant in increasing chemiluminescence in peritoneal macrophages during phagocytosis of zymosan particles.
To further support the evidence that Bru-Pel shares with other immunomodulators the capacity to enhance host resistance and activate macrophages, Bru-Pel was shown to protect mice from infection with a lethal inoculation of L. monocytogenes. These results extend the antiviral and antitumor activity of Bru-Pel to a bacterial infection and support the hypothesis that Bru-Pel enhances reticuloendothelial cell function.
The data are not intended to imply that activation of macrophages is the only mechanism of action, but its capacity to activate macrophage clearly could be an important mechanism through which Bru-Pel acts to modulate host resistance.
